Truist Financial
AERI

Truist Financial’s Aerie Pharmaceuticals AERI Stock Holding History

Truist Financial’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35,533
Closed -$266K – 2715
2022
Q2 		$266K Buy
+35,533
New +$250K ﹤0.01% 2292
2021
Q4 		– Sell
-29,133
Closed -$332K – 2887
2021
Q3 		$332K Buy
29,133
+788
+3% +$11.5K ﹤0.01% 2274
2021
Q2 		$454K Buy
28,345
+1,436
+5% +$24.6K ﹤0.01% 2122
2021
Q1 		$481K Buy
26,909
+13,694
+104% +$237K ﹤0.01% 1987
2020
Q4 		$178K Buy
13,215
+2,244
+20% +$27.1K ﹤0.01% 2401
2020
Q3 		$129K Buy
+10,971
New +$134K ﹤0.01% 2330
2020
Q1 		– Sell
-11,543
Closed -$279K – 2613
2019
Q4 		$279K Buy
+11,543
New +$239K ﹤0.01% 2192

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Truist Financial's AERI Position: Q3 2022 in Review

Truist Financial sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 35,533 shares — an estimated $266K sold.

Truist Financial first reported a position in AERI in Q4 2019 and held it in 7 quarters. The position peaked at $481K in Q1 2021. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

  • Truist Financial reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Truist Financial sold 35,533 Aerie Pharmaceuticals shares in Q3 2022, an estimated $266K.
  • Truist Financial first reported a position in Aerie Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Truist Financial's Aerie Pharmaceuticals position peaked at $481K in Q1 2021.
  • 156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Truist Financial's 13F filing for Q3 2022, filed 26 Oct 2022.